| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Tanzisertib targets the c-Jun N-terminal kinases (JNK1, JNK2, and JNK3), which are members of the MAPK family involved in stress responses, inflammation, and apoptosis. It inhibits these kinases with IC50 values of 61 nM, 7 nM, and 6 nM, respectively. It is a potent inhibitor of JNK1/2/3.
|
|---|---|
| ln Vitro |
Tanzisertib (CC-930) inhibits the synthesis of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1]. In FC-loaded WT hepatocytes, tanzisertib (CC-930) (1-2 μM) completely abolishes apoptosis and necrosis[2]. In systemic sclerosis, tanzisertib (CC-930) inhibits the JNK pathway that is triggered by pro-fibrotic cytokines[3].
In vitro, Tanzisertib is a potent inhibitor of JNK1/2/3, with IC50 values of 61/7/6 nM. It shows remarkable selectivity in a panel of 240 kinases, with EGFR being the only non-MAP kinase inhibited more than 50% at 3 µM (IC50 = 0.38 µM). |
| ln Vivo |
Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model[1]. Tanzisertib (CC-930) (150 mg/kg) can cause the regression of pre-existing fibrosis while also preventing the development of fibrosis in various models[3].
In vivo, Tanzisertib has been evaluated in Phase II clinical trials for idiopathic pulmonary fibrosis (IPF), indicating its potential as an antifibrotic agent. It is orally bioavailable and has shown efficacy in preclinical models of fibrosis. |
| Enzyme Assay |
CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK [Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM] and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
In vitro kinase assays are performed using purified JNK1, JNK2, and JNK3 enzymes. The compound is incubated with the kinase and a substrate, and the degree of phosphorylation is measured to determine IC50 values. |
| Cell Assay |
In 96-well plates with 1 µM Tanzisertib (CC-930), fibroblasts from patients with systemic sclerosis (SSc) are incubated for 20 hours. The cells are then given an additional 4 hours of incubation at 37°C before receiving MTT at a final concentration of 1 mg/mL. All other results are normalized to untreated cells while mock-treated fibroblasts serve as the standard.
Cells are treated with Tanzisertib, and its effect on JNK-mediated signaling is measured by assessing the phosphorylation of downstream targets like c-Jun. Its effect on cell proliferation, apoptosis, or fibrosis-related gene expression can also be assessed. |
| Animal Protocol |
A modified version of the bleomycin-induced dermal fibrosis model is used to assess the regression of fibrosis on inhibition of JNK. In this model, significant dermal fibrosis is already present three weeks after the start of the challenge and is treated with bleomycin. The results of six different groups, comprising a total of 40 mice, are analyzed. NaCl is subcutaneously injected into the first group of mice for a total of six weeks. In order to assess the level of fibrosis prior to treatment and to prevent spontaneous fibrosis regression, the second group receives injections of bleomycin for 3 weeks, followed by injections of NaCl for an additional 3 weeks. After six weeks of bleomycin injections, the third group of mice is euthanized. The final three weeks of a continuous six-week challenge with bleomycin are spent administering Tanzisertib (CC-930) to the fourth and fifth groups at doses of 50 mg/kg and 150 mg/kg, respectively. The sixth group is a positive control group made up of mice that were given bleomycin for six weeks before being given imatinib at a dose of 50 mg/kg for the final three weeks.
The in vivo efficacy of Tanzisertib has been evaluated in clinical trials for IPF. Preclinically, it would be tested in animal models of fibrosis to measure its effect on collagen deposition and other fibrotic markers. |
| ADME/Pharmacokinetics |
Tanzisertib is orally bioavailable. Its pharmacokinetic properties have been characterized in preclinical species and in clinical trials to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The safety and tolerability of Tanzisertib have been assessed in preclinical toxicology studies and in Phase I and II clinical trials. As a JNK inhibitor, its potential for off-target effects and toxicities has been evaluated.
|
| References |
|
| Additional Infomation |
Tanzisertib has been used in trials to study the treatment of diseases such as fibrosis, discoid lupus erythematosus, pulmonary fibrosis, interstitial lung disease, and interstitial lung disease.
Tanzisertib (CC-930) is an investigational drug for the treatment of fibrotic diseases. It has been evaluated in Phase II clinical trials for IPF, demonstrating its progression in clinical development. It is a potent, specific, and orally bioavailable JNK inhibitor. |
| Molecular Formula |
C21H23F3N6O2
|
|
|---|---|---|
| Molecular Weight |
448.441534280777
|
|
| Exact Mass |
448.183
|
|
| CAS # |
899805-25-5
|
|
| Related CAS # |
|
|
| PubChem CID |
11597537
|
|
| Appearance |
Off-white to yellow solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
626.4±65.0 °C at 760 mmHg
|
|
| Flash Point |
332.6±34.3 °C
|
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
|
| Index of Refraction |
1.713
|
|
| LogP |
2.08
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
10
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
618
|
|
| Defined Atom Stereocenter Count |
1
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2300 mL | 11.1498 mL | 22.2995 mL | |
| 5 mM | 0.4460 mL | 2.2300 mL | 4.4599 mL | |
| 10 mM | 0.2230 mL | 1.1150 mL | 2.2300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Bioorg Med Chem Lett.2012 Feb 1;22(3):1433-8. |
Bioorg Med Chem Lett.2012 Feb 1;22(3):1433-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
